Triple negative breast cancer associated with paraneoplastic dermatomyositis: Case report and literature review.
DOI:
https://doi.org/10.35509/01239015.707Keywords:
dermatomyositis, paraneoplastic syndrome, triple-negative breast carcinoma, Raynaud·s phenomenon, chemotherapy, phenomenon cytotoxic therapy, corticosteroidAbstract
Dermatomyositis (DM) is a well-defined type of immune-mediated inflammatory myopathy, with specific involvement of the skeletal muscle and with variable involvement of the skin and other organs. It is characterized by proximal muscle weakness, pathognomonic skin lesions of dermatomyositis such as Gottron's sign, purplish or heliotrope rash, and evidence of muscle inflammation by elevated enzymes, myopathic changes on electromyography, and abnormal muscle biopsy. It has a well-established association with different types of cancer, but its association with breast cancer is rare. When both occur concomitantly, their diagnosis requires a multidisciplinary study to guide the paraneoplastic origin versus a primarily autoimmune etiology that may require targeted immunosuppressive therapy. We describe the case of a patient with a simultaneous diagnosis of triple negative breast cancer and criteria for dermatomyositis as a paraneoplastic manifestation.
References
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (8): 403-7.
Linklater H, Pipitone N, Rose MR, Norwood F, Campbell R, Salvarani C, et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 2013; 31 (5):767-9.
Bottai M, Tiärnlund A, Santoni G, Weth V, Pilkington C, de Visser M, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 2017; 14; 3 (2): e000507. doi: 10.1136/rmdopen-2017-000507.
Leclair V, Lundberg I. New myositis classification criteria-what we have learned since Bohan and Peter. Curr Rheumatol Rep 2018
Stertz O. Polymyositis. Berl Klin Wochenschr 1916; 53:489
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344.
Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 1976; 84:68
Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ 3rd. Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 1986; 61:645.
Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326:363.
Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001; 85:41.
Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 2015; 42:282.
Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995; 6:9.
Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134:1087.
Chen YJ, Wu CY, Huang YL, et al. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010; 12:R70.
Cox NH, Lawrence CM, Langtry JA, Ive FA. Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy. Arch Dermatol 1990; 126:61.
Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357:96.
Hendren E, Vinik O, Faragalla H. Breast cancer and dermatomyositis: a case study and literature review. Curr Oncol. 2017 Oct;24(5):e429-e433.
Selva O’Callaghan A et al. Miopatías inflamatorias. Dermatomiositis, polimiositis y miositis con cuerpos de inclusión, Reumatol Clin. 2008;4(5):197-206
Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591.
Trallero-Araguás E, Labrador-Horrillo M, Selva-O'Callaghan A, et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010; 89:47.
Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66:1345.
Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65:2954.
H. Chinoy, N. Fertig, C.V. Oddis, W.E. Ollier, R.G. Cooper. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.
Ann Rheum Dis, 66 (2007), pp. 1345-1349
Taborda AL, Azevedo P, Isenberg DA. Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. Clin Exp Rheumatol 2014; 32 (2): 188-93.
Smuder AJ. Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity. Am J Physiol Regul Integr Comp Physiol. 2019;317(5):R662-R672. doi:10.1152/ajpregu.00161.2019
Baig S, Paik JJ, Inflammatory muscle disease e An update, Best Practice & Research Clinical Rheumatology, https://doi.org/10.1016/j.berh.2019.101484
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
